View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 11, 2018

Wright Medical completes $435m acquisition of Cartiva

Dutch medical device company Wright Medical Group has closed the acquisition of US-based orthopaedic devices maker Cartiva.

Dutch medical device company Wright Medical Group has closed the acquisition of US-based orthopaedic devices maker Cartiva.

The company agreed to buy Cartiva for a total consideration of $435m in August this year. Cartiva primarily develops devices for the treatment of osteoarthritis of the great toe.

The acquisition bolsters Wright Medical’s Extremities business with the addition of Cartiva’s premarket approved technology called Synthetic Cartilage Implant (SCI) designed for high-volume foot and ankle procedures.

SCI is made of a biocompatible organic polymer that is durable with low friction. It can be implanted in approximately 35 minutes and is similar to natural cartilage in functionality.

“The acquisition bolsters Wright Medical’s Extremities business with the addition of Cartiva’s premarket approved technology called Synthetic Cartilage Implant (SCI) designed for high-volume foot and ankle procedures.”

The implant is said to reduce joint pain while retaining the foot’s natural movement, mobility and range of motion. This enables patients to return to their daily functions and activities faster than those treated through a fusion procedure.

Wright Medical Group president and CEO Robert Palmisano said: “With approximately 120,000 procedures for great toe arthritis performed each year in the US, we believe that this technology provides a proven alternative to fusion that reduces joint pain without sacrificing the foot’s natural movement and retains mobility and range of motion.”

In addition to the US, SCI has regulatory approvals in Canada, European Union (EU), Brazil, Chile and Australia.

Wright Medical is focussed on the development of extremities and biologics products. It offers surgical solutions for the upper and lower extremities and biologics markets.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU